Level of evidence supporting the Chinese cardiovascular disease clinical practice guidelines and its evolution in the past two decades

[1]  Deepak L. Bhatt,et al.  Methodological Standards for the Design, Implementation, and Analysis of Randomized Trials in Cardiac Surgery: A Scientific Statement From the American Heart Association , 2021, Circulation.

[2]  P. Serruys,et al.  Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial , 2021, The Lancet.

[3]  Weili Zhang,et al.  Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. , 2021, The New England journal of medicine.

[4]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[5]  Deepak L. Bhatt,et al.  Randomized Trials in Cardiac Surgery: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.

[6]  Changsheng Ma,et al.  Current state of cardiovascular research in China , 2019, Nature Reviews Cardiology.

[7]  C. Anderson,et al.  Epidemiology of Cardiovascular Disease in China and Opportunities for Improvement: JACC International. , 2019, Journal of the American College of Cardiology.

[8]  Yichong Li,et al.  Burden of Cardiovascular Diseases in China, 1990-2016: Findings From the 2016 Global Burden of Disease Study , 2019, JAMA cardiology.

[9]  R. Califf,et al.  Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 , 2019, JAMA.

[10]  P. Noseworthy,et al.  Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10‐Year Assessment , 2019, Journal of the American Heart Association.

[11]  Y. Zhang,et al.  Traditional Chinese Medicine for Cardiovascular Disease: Evidence and Potential Mechanisms , 2017, Deutsche Zeitschrift für Akupunktur.

[12]  Xinyang Hu,et al.  Chinese Basic Cardiovascular Research in Transition. , 2016, Circulation research.

[13]  G. Stone,et al.  Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. , 2015, JAMA.

[14]  W. Yao,et al.  A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. , 2013, Journal of the American College of Cardiology.

[15]  R. Califf,et al.  Scientific evidence underlying the ACC/AHA clinical practice guidelines. , 2009, JAMA.

[16]  S. Shortell,et al.  Improving patient care by linking evidence-based medicine and evidence-based management. , 2007, JAMA.

[17]  A. Detsky,et al.  Evidence-based medicine. A new approach to teaching the practice of medicine. , 1992, JAMA.